BCL2L11 and cancer: In our study, we also discovered that 4bHWE can modulate the alternative splicing of numerous candidate biomarker transcripts such as AIMP2, BCL2L11, BIRC5, CASP3, CEACAM1, CPE, FGFR2, FN1, FPGS, HIF1A, KLF6, MCL1, MDM2, MKNK2, TERT, and VEGFA. This suggests that 4bHWE may have potential for use in cancer treatment.